Skip to content
CLLS·Nasdaq·US

Cellectis

Cellectis is a clinical-stage biotechnology company focused on genome engineering and therapeutic development. It has historically developed allogeneic CAR-T cell therapies and now is pivoting toward in vivo gene editing programs.

Recent Activity

Updated Oct 31, 2026
–Cellectis presented preclinical data at ESGCT 2026 showing that its .HEAL-101 program achieved 70% in vivo editing of human APOC3 after a single administration.
–In a murine disease model, a single dose of .HEAL-101 reduced triglycerides by 76%, according to the Cellectis data presented at ESGCT 2026.

Past updates are part of the Pro plan.

Thematic Position

CLLS

Relationship Groups

Customers1
Partners2
Licensing4
Competitors24

Relationship details are part of the Pro plan.

Recent Discoveries

Recent discoveries are part of the Pro plan.

Ended Relationships

15 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

clinical holdregulatory action
FDA clinical holds on Cellectis's AMELI-01 and MELANI-01 studies
SEC 20-FMar 20, 2026

The full regulatory passage is part of the Pro plan.

5 more · Regulatory and geopolitical insights are part of the Pro plan.